Related Experiment Video

Updated: May 25, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K

The role of endothelin receptor antagonists in kidney disease

Xiaoting Ma1, Yuyang Liang1, Wenmin Chen1

  • 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China.

Renal Failure
|February 27, 2025
PubMed

Insights

Endothelin receptor antagonists (ERAs) show promise in treating kidney diseases by reducing proteinuria and improving glomerular filtration rate (GFR). These therapies target the harmful effects of endothelin (ET) in conditions like chronic kidney disease.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiovascular Research

Background:

  • Kidney diseases affect over 850 million people globally, encompassing acute kidney injury and chronic kidney disease.
  • Endothelin (ET) plays a critical role in the onset and progression of kidney diseases.
  • Pathological conditions elevate ET, activating endothelin receptor type A, leading to proteinuria and reduced glomerular filtration rate (GFR).

Purpose of the Study:

  • To review the mechanisms of action of endothelin receptor antagonists (ERAs) in treating kidney disease.
  • To evaluate the efficacy and safety of ERAs in preclinical and clinical studies.
  • To explore future prospects for ERAs in managing kidney diseases.

Main Methods:

  • Review of preclinical and clinical studies on endothelin receptor antagonists (ERAs).
  • Analysis of the impact of ERAs on proteinuria and glomerular filtration rate (GFR).
  • Discussion of the role of endothelin (ET) in kidney disease pathogenesis.

Main Results:

  • Endothelin receptor antagonists (ERAs) have demonstrated significant efficacy in reducing proteinuria.
  • ERAs have shown potential in improving glomerular filtration rate (GFR), thereby slowing disease progression.
  • Studies confirm the link between elevated endothelin (ET) and pathological kidney conditions.

Conclusions:

  • Endothelin receptor antagonists (ERAs) represent a promising therapeutic strategy for slowing the progression of kidney diseases.
  • ERAs effectively mitigate the adverse effects of endothelin (ET) on kidney function.
  • Further research into ERAs offers potential for improved management of chronic kidney disease and acute kidney injury.
Keywords:
Endothelinacute kidney injurychronic kidney diseaseendothelin receptor antagonistkidney disease

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.5K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
123
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
447
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K